| Tan, Lijie |
POINT, NCT04513418: Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy |
|
|
| Recruiting | 3 | 244 | RoW | Preoperative immunonutrition | Hecheng Li M.D., Ph.D, Shanghai Chest Hospital, Shanghai Zhongshan Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Ningbo Medical Center Lihuili Hospital, Zhejiang Cancer Hospital, Fujian Medical University Union Hospital, Shanghai East Hospital | Esophageal Neoplasms | 03/25 | 12/28 | | |
| Recruiting | 3 | 360 | RoW | esophagectomy, minimally invasive esophagectomy | Shanghai Chest Hospital, Ruijin Hospital, Changhai Hospital, Shanghai Zhongshan Hospital, The First Affiliated Hospital of Nanchang University | Esophageal Cancer, Esophageal Carcinoma | 12/24 | 12/24 | | |
NCT05043688: Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. |
|
|
| Recruiting | 3 | 426 | RoW | Camrelizumab, radiotherapy | Zhigang Li, Jiangsu HengRui Medicine Co., Ltd. | Resectable Esophageal Squamous Cell Carcinoma | 12/28 | 12/30 | | |
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 3 | 663 | RoW | Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel | Shanghai Junshi Bioscience Co., Ltd. | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 05/27 | 05/27 | | |
NCT04973306: Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC |
|
|
| Recruiting | 2/3 | 176 | RoW | Neoadjuvant Chemoradiotherapy, Tislelizumab, anti-PD-1 antibody, Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended) | Shanghai Zhongshan Hospital, Beijing Cancer Hospital, Shanghai Chest Hospital, First Affiliated Hospital of Wenzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, Ningbo Medical Center Lihuili Hospital, The First People's Hospital of Changzhou, Zhongshan Hospital, Fudan University (Xiamen Branch), Xuhui Central Hospital, Shanghai, Shanghai Minhang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Tongji Hospital, Sun Yat-sen University, Shanghai Fifth People's Hospital | Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III | 07/24 | 07/27 | | |
| Recruiting | 2 | 30 | RoW | PD-L1 Antibody SHR-1316, PD-L1 antibody | Shanghai Zhongshan Hospital | Oesophageal Squamous Cell Carcinoma | 07/22 | 12/22 | | |
NCT06637163: Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC |
|
|
| Not yet recruiting | 2 | 100 | RoW | Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy, Paclitaxel + Carboplatin + Radiotherapy | Shanghai Zhongshan Hospital | Esophageal Squamous Cell Carcinoma | 04/26 | 04/27 | | |
| Recruiting | N/A | 400 | RoW | Goal-directed EN therapy, Conventional EN therapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer | 08/26 | 05/31 | | |
